Pembrolizumab plus docetaxel used to treat patients with metastatic castration-resistant prostate cancer

SG monotherapy demonstrates a high response rate in PT-ineligible patients with mUC who progressed after CPI therapy

Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC

Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer

Latest in PARP inhibitors and combination therapies for prostate cancer

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Plasma miR371 detects MRD and early relapse of germ cell tumours

Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

Changes in planned disease management after PET/CT in men with biochemically recurrent prostate cancer and low PSA levels

Abiraterone acetate/prednisone + apalutimide and ADT with post-op SRT may improve PFS and MFS after prostatectomy

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma